Every Form 4 that VAXART INC (VXRT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VXRT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VXRT filings page.
Vaxart director Kevin Finney reported equity awards dated July 16, 2026. He received 39,400 shares of Common Stock upon vesting of restricted stock units, bringing his direct holdings to 244,171 shares. He was also granted 78,700 stock options with a $0.5149 exercise price, expiring July 16, 2036. Both the RSU shares and options vest on the earlier of the date immediately prior to Vaxart’s 2027 annual meeting of stockholders and July 16, 2027, the first anniversary of the grant.
Vaxart, Inc. director James B. Breitmeyer reported equity awards dated July 16, 2026. He acquired 8,315 shares of common stock in connection with restricted stock units that will vest on the earlier of the date immediately prior to the 2027 annual stockholder meeting and July 16, 2027, bringing his direct holdings to 87,115 shares. He was also granted options on 16,610 shares at an exercise price of $0.5149 per share, expiring July 16, 2036, with the options subject to the same vesting schedule.
Vaxart, Inc. director Elaine J Heron reported equity compensation awards dated July 16, 2026. She acquired 39,400 shares of Common Stock in connection with restricted stock units, bringing her direct common share holdings to 135,966. She was also granted 78,700 Stock Options to buy Common Stock at an exercise price of $0.5149 per share, expiring on July 16, 2036. Footnotes state that both the restricted stock unit award and the option award vest on the earlier of the date immediately prior to Vaxart’s 2027 annual meeting of stockholders and July 16, 2027.
Vaxart, Inc. director Watson W. Mark reported compensation-related equity awards. He acquired 39,400 shares of common stock at no cost in connection with restricted stock units, and a grant of 78,700 stock options with a $0.5149 exercise price, expiring July 16, 2036. Both the shares and options are scheduled to vest on the earlier of the date immediately prior to Vaxart’s 2027 annual stockholders’ meeting and July 16, 2027. Following these awards, he directly holds 173,525 common shares and 78,700 options.
Vaxart, Inc. director David E. Wheadon received equity awards on July 16, 2026. He was granted 39,400 shares of common stock, bringing his direct holdings to 86,150 shares, plus stock options for 78,700 shares at an exercise price of $0.5149, expiring July 16, 2036. Both the stock award and options vest on the earlier of the date immediately prior to Vaxart’s 2027 annual meeting of stockholders and July 16, 2027, the first anniversary of the grant.
Vaxart, Inc. director Watson W. Mark reported an open-market purchase of 10,000 shares of Common Stock on May 22, 2026 at $0.653 per share. Following this transaction, he directly holds 134,125 shares of Vaxart common stock.
Vaxart, Inc. Chief Financial Officer Jeroen Nicolaas Grasman reported a tax-related share disposition connected to vested restricted stock units. On May 19, 2026, 31,395 shares of common stock were withheld by the company at $0.61 per share to satisfy income tax withholding and remittance obligations. This was a non-market transaction used to settle taxes rather than an open-market sale. After this withholding, Grasman directly held 545,605 shares of Vaxart common stock.
Vaxart, Inc. director James B. Breitmeyer reported receiving equity compensation in the form of common shares and stock options. He was granted 78,800 shares of Common Stock upon vesting of restricted stock units, with the underlying award vesting in three equal annual installments starting from the grant date, subject to his continued service on the Board of Directors.
He was also granted a stock option for 157,400 shares of Common Stock at an exercise price of $0.7399 per share, expiring on April 23, 2036. The option vests in three equal annual installments from the grant date, also conditioned on continued Board service. These are compensation-related awards rather than open‑market purchases or sales.
Vaxart, Inc. SVP and Chief Scientific Officer Sean Tucker reported a routine tax-related share disposition tied to vested RSUs. On March 28, 2026, 3,924 shares of common stock were withheld by the company at $0.65 per share to cover income tax obligations. After this, Tucker held 882,811 common shares directly, plus 51,465 shares in joint tenancy with Frances Chang and 9,060 shares held by his spouse, both reported as indirect ownership.
Vaxart, Inc. Chief Medical Officer James F. Cummings reported a routine tax-withholding transaction involving company stock. On March 28, 2026, 3,292 shares of Common Stock were withheld by Vaxart at $0.65 per share to cover income tax obligations from vested RSUs.
After this withholding, Cummings directly holds 924,177 shares of Vaxart common stock, including 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. This event reflects tax settlement on equity compensation rather than an open-market sale.
Vaxart, Inc. executive Edward B. Berg, SVP and General Counsel, reported a tax-related share disposition tied to restricted stock units. On the RSU vesting date, 36,418 shares of common stock at $0.694 per share were withheld by the company to satisfy income tax obligations, rather than sold in the open market. After this withholding, Berg directly holds 755,368 common shares, including 70,781 shares previously acquired under Vaxart’s 2022 Employee Stock Purchase Plan.
Vaxart, Inc.’s Chief Medical Officer, James F. Cummings, reported a routine tax-related share disposition. On March 24, 2026, 30,551 shares of common stock were withheld by the company at $0.694 per share to cover income tax obligations from vested RSUs. After this withholding, he directly holds 927,469 common shares, which includes 75,618 shares acquired under Vaxart’s 2022 Employee Stock Purchase Plan. This event reflects compensation-related tax settlement rather than an open-market sale.
Vaxart, Inc. President and CEO Steven Lo reported a tax-related share disposition tied to restricted stock units (RSUs). On March 24, 2026, 126,028 shares of common stock were withheld by the company to satisfy income tax withholding and remittance obligations upon RSU vesting, rather than sold in the open market.
Following this withholding, Lo directly holds 2,485,606 shares of Vaxart common stock and indirectly holds 100,000 shares through the Lo Family Trust. The filing reflects routine equity compensation and associated tax treatment rather than a discretionary buy or sell decision.
Vaxart, Inc. SVP and Chief Scientific Officer Sean Tucker reported a tax-withholding share disposition related to vested RSUs. On March 24, 2026, 36,418 shares of common stock were withheld by the company at $0.694 per share to cover income tax obligations on RSUs that vested that day.
After this non-market, tax-related disposition, Tucker directly holds 886,735 shares. He also has indirect holdings of 51,465 shares in joint tenancy with Frances Chang and 9,060 shares held by his spouse, as reflected in the filing’s ownership entries.
Vaxart, Inc. reported an insider equity transaction by SVP and General Counsel Edward B. Berg related to tax withholding on vested stock awards. On March 18, 2026, 8,072 shares of common stock were disposed of at $0.6346 per share to satisfy income tax withholding obligations in connection with the net settlement of RSUs that vested on that date. This was not an open-market sale but a routine, issuer-withheld share disposition for taxes. Following the transaction, Berg directly held 791,786 common shares, which includes 70,781 shares acquired under Vaxart’s 2022 Employee Stock Purchase Plan.
Vaxart, Inc. Chief Medical Officer James F. Cummings reported a routine share withholding tied to restricted stock units. On March 18, 2026, 6,772 shares of common stock were withheld at $0.6346 per share to cover income tax obligations for vested RSUs. After this tax-withholding disposition, he directly holds 958,020 shares of Vaxart common stock, which includes 75,618 shares acquired under the 2022 Employee Stock Purchase Plan.
Vaxart, Inc. President and CEO Steven Lo reported a tax-related share disposition tied to RSU vesting. On March 18, 2026, 22,425 shares of common stock were withheld by the company at $0.6346 per share to cover income tax obligations on vested RSUs, a non-market transaction coded as "F." After this withholding, Lo directly owned 2,611,634 common shares and indirectly held 100,000 additional shares through the Lo Family Trust, indicating that his overall equity stake remains substantial despite the routine tax withholding.
Vaxart, Inc. senior executive Sean Tucker reported a routine tax-related share disposition tied to restricted stock unit vesting. On March 18, 2026, 8,072 shares of common stock were withheld by the company to cover income tax obligations from RSUs that vested on that date, a non-market transaction rather than an open-market sale. After this withholding, Tucker directly holds 923,153 common shares and has additional indirect holdings of 51,465 shares in joint tenancy with Frances Chang and 9,060 shares held by his spouse.
Vaxart, Inc. director and CEO Steven Lo received new equity awards as part of his compensation. He was granted stock options for 1,543,000 shares of common stock at an exercise price of $0.6795 per share, expiring on March 16, 2036. These options vest 25% on March 16, 2027 and then in 36 equal monthly installments until fully vested on March 16, 2030.
Lo also received a grant of 846,500 shares of common stock upon vesting of restricted stock units. Those units vest 25% on each anniversary of the vesting commencement date of March 16, 2026, fully vesting on the fourth anniversary. Following these awards, he directly holds 2,634,059 common shares and 1,543,000 options, plus an indirect holding of 100,000 shares through the Lo Family Trust.
Vaxart, Inc. SVP and Chief Scientific Officer Sean Tucker reported equity awards rather than open-market trades. He received a stock option covering 410,000 shares of common stock at an exercise price of $0.6795 per share, expiring on March 16, 2036. The option vests 25% on March 16, 2027 and then in 36 equal monthly installments until March 16, 2030.
He also acquired 200,000 shares of common stock at no cash cost in connection with restricted stock units, which are scheduled to vest 25% on each anniversary of the March 16, 2026 vesting commencement date until the fourth anniversary. Following these awards, he directly holds 931,225 common shares, with additional indirect holdings of 51,465 shares in joint tenancy and 9,060 shares held by his spouse.
Vaxart, Inc.’s Chief Financial Officer, Jeroen Nicolaas Grasman, reported equity compensation grants. He was awarded 227,000 shares of Common Stock upon vesting of restricted stock units, bringing his direct Common Stock holdings to 577,000 shares.
He also received a stock option covering 455,000 shares of Common Stock at an exercise price of $0.6795 per share, expiring on March 16, 2036. The restricted stock units vest 25% on March 16, 2026 and then annually so they are fully vested on the fourth anniversary, while the option vests 25% on March 16, 2027 and then in 36 equal monthly installments until fully vested on March 16, 2030. These are compensation-related awards rather than open-market purchases.
Vaxart, Inc. reported that Chief Medical Officer James F. Cummings received new equity awards on March 16, 2026. He was granted stock options for 455,000 shares of common stock at an exercise price of $0.6795 per share, expiring on March 16, 2036. The option vests 25% on March 16, 2027 and then in 36 equal monthly installments until March 16, 2030. He also received 227,000 shares of common stock through vesting of restricted stock units, which vest 25% on each anniversary of March 16, 2026 over four years. Following these grants, he holds 964,792 shares of common stock directly.
Vaxart, Inc. SVP and General Counsel Edward B. Berg received new equity awards as part of his compensation. On March 16, 2026, he was granted 115,000 shares of common stock upon vesting of restricted stock units, with 25% of the units vesting on each anniversary of the March 16, 2026 vesting commencement date until fully vested after four years.
He was also granted a stock option for 225,000 shares of common stock at an exercise price of $0.6795 per share, expiring on March 16, 2036. The option vests 25% on March 16, 2027 and then in 36 equal monthly installments so it is fully vested by March 16, 2030. Following these grants, Berg directly holds 799,858 common shares.
Vaxart, Inc. Chief Medical Officer James F. Cummings reported an automatic share withholding tied to restricted stock units (RSUs). On February 2, 2026, 7,965 shares of common stock were withheld at $0.6085 per share to satisfy income tax obligations upon RSU vesting. After this transaction, he beneficially owned 737,792 common shares, which includes 75,618 shares acquired under Vaxart’s 2022 Employee Stock Purchase Plan. The transaction was reported as directly held ownership.
Vaxart, Inc. SVP and General Counsel Edward B. Berg reported a routine tax-related share withholding. On February 2, 2026, 9,265 shares of common stock were withheld at $0.6085 per share to cover income tax obligations from vested RSUs. After this transaction, Berg directly beneficially owned 684,858 common shares, which includes 70,781 shares acquired through Vaxart’s 2022 Employee Stock Purchase Plan.
Vaxart, Inc. senior vice president and chief scientific officer Sean Tucker reported a routine share withholding tied to restricted stock units (RSUs). On February 2, 2026, 9,265 shares of Vaxart common stock were withheld by the company at $0.6085 per share to cover income tax obligations upon RSU vesting.
After this tax-related withholding, Tucker beneficially owned 731,225 common shares directly. He also reported indirect holdings of 51,465 shares in joint tenancy with Frances Chang and Sean Tucker, and 9,060 shares held by his spouse.
Vaxart, Inc. insider Michael Finney reported equity transactions in company stock. On December 4, 2025, he acquired 151,351 shares of common stock at a price of $0, reflecting the full vesting of previously granted restricted stock units. On the same date, 54,153 shares were disposed of at $0.37 per share, representing shares withheld by Vaxart to cover income tax obligations tied to the RSU vesting.
After these transactions, Finney beneficially owns 1,787,559 shares of Vaxart common stock directly, plus 100,000 shares held indirectly through the Lo Family Trust. The reported holdings also include 57,723 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan.
Vaxart, Inc. director reports open-market stock purchases. A Vaxart (VXRT) director bought 15,000 shares of common stock on 11/17/2025 at a price of $0.41 per share and an additional 5,000 shares at $0.407 per share, both coded as open-market purchases. Following these transactions, the director beneficially owns 124,125 shares of Vaxart common stock in direct ownership form. The report notes that the filing was submitted late due to delays in receiving EDGAR access codes.
Vaxart, Inc. (VXRT) reported an insider share purchase by a director. On 11/17/2025, the director bought 23,217 shares of common stock in an open-market transaction at $0.393 per share and a further 16,783 shares at $0.405 per share. After these purchases, the director beneficially owned 96,566 shares, held directly. The filing notes the person’s role as a director and confirms the report is filed by a single reporting person.